Pharmaceuticals · Nasdaq Copenhagen
Novo Nordisk
Datos de precio: widget de TradingView abajo
Novo Nordisk (NOVO-B) — Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
Why people search for it: Searched as Europe’s obesity/diabetes pharma leader — Ozempic/Wegovy keep the ticker in global headlines.
Cargando gráfico…
Open NOVO-B chart in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
Cargando gráfico…
📐 Análisis técnico
Cargando gráfico…
Resumen de indicadores de TradingView (medias móviles, osciladores). Una señal mecánica, no un consejo.
Open technicals in TradingView Affiliate: if you subscribe via our TradingView link, Hodlia may earn a commission at no extra cost to you.
📊 Fundamentales
Cargando gráfico…
🏢 Perfil de la empresa
Cargando gráfico…
📰 Últimas noticias de NOVO-B
Cargando gráfico…
🧩 Qué es
Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
⚡ Por qué es interesante
It became one of Europe’s most valuable companies as demand for weight-loss and diabetes drugs surged worldwide, keeping NOVO-B in constant search interest.
⚠️ Riesgos clave
Valuation prices in rapid growth; competition in GLP-1, supply constraints, pricing pressure and any safety headlines can move the stock sharply. Currency (DKK/EUR) matters for international investors.
👀 Qué vigilar
GLP-1 sales, manufacturing capacity, rival trial data and US pricing/reimbursement news.
Written by the Hodlia.fi editorial team. Education only — not financial advice, no price predictions. Contains a TradingView affiliate link.
❓ Novo Nordisk: preguntas frecuentes
¿Qué es Novo Nordisk (NOVO-B)?
Novo Nordisk is a Danish pharmaceutical company known for diabetes and obesity treatments, including GLP-1 medicines such as Ozempic and Wegovy.
¿Por qué se sigue a Novo Nordisk?
It became one of Europe’s most valuable companies as demand for weight-loss and diabetes drugs surged worldwide, keeping NOVO-B in constant search interest.
Why do people search for Novo Nordisk?
Searched as Europe’s obesity/diabetes pharma leader — Ozempic/Wegovy keep the ticker in global headlines.
¿Cuáles son los principales riesgos de Novo Nordisk?
Valuation prices in rapid growth; competition in GLP-1, supply constraints, pricing pressure and any safety headlines can move the stock sharply. Currency (DKK/EUR) matters for international investors.
¿Qué debo vigilar de Novo Nordisk?
GLP-1 sales, manufacturing capacity, rival trial data and US pricing/reimbursement news.
¿Es Novo Nordisk una buena inversión?
Hodlia no ofrece asesoramiento de inversión. Que Novo Nordisk te convenga depende de tus objetivos, tu horizonte temporal y cuántas pérdidas puedes asumir. Las acciones individuales pueden caer mucho incluso con los mercados en calma. Lee los riesgos de arriba, compara con una alternativa diversificada y considera un asesoramiento independiente.